METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Doctors track new stomach cancer Drug's Real-World side effects
Disease control Recruiting nowThis study is collecting information on the safety of VYLOY, an already approved drug, for people in South Korea with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 377 patients receiving VYLOY as part of their standard care will be …
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Korea, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Breakthrough cancer drug offered early to eligible stomach cancer patients
Disease control AVAILABLEThis program provides early access to the drug zolbetuximab for people with advanced stomach or gastroesophageal junction cancer who haven't had prior treatment. It's for patients whose cancer tests positive for a specific protein called claudin18.2. Participants receive zolbetux…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for advanced stomach cancer: phase 3 trial tests targeted combo therapy
Disease control Recruiting nowThis study is testing whether adding a new drug called zolbetuximab to standard immunotherapy and chemotherapy helps people with advanced stomach or gastroesophageal (GEJ) cancer live longer. It is for adults whose cancer has spread, cannot be removed by surgery, and has specific…
Matched conditions: METASTATIC GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC